Eric Warren
Known title: Chief Commercial OfficerCIK: 0001916048
Associated companies
Transaction History
| MLYS | ▲ Buy | Option Exercise | 7,438 | $98K | 9/21/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 7,438 | $209K | 9/21/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 7,437 | $98K | 8/21/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 7,437 | $193K | 8/21/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 7,438 | $98K | 7/21/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 7,438 | $200K | 7/21/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 104,124 | $1.4M | 6/26/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 104,124 | $2.7M | 6/26/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.